Tango Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 13G, Stake over 5%, passiveAug 14 →InsidersNo open-market buys. 6 insiders sold $9.5M, 9 of 16 sales on a 10b5-1 plan.→HoldersRTW Investments 8.3%BlackRock 7.4%FMR 7.3%→Financing →PeersClosest companies: RLAY, TYRA, BDTX→
From the filings
Figures
- Revenue
- $53.8Mlast 12 months
- Net income
- −$123.7Mlast 12 months
- Operating cash flow
- −$141.5Mlast 12 months
- Cash and equivalents
- $345.6Mat the last balance sheet
- Shares outstanding
- 168.4M shareson issue